Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults

BACKGROUND: Management of drug–drug interactions (DDIs) for ensitrelvir, a novel 3-chymotrypsin-like protease inhibitor of SARS-CoV-2 infection is crucial. A previous clinical DDI study of ensitrelvir with midazolam, a clinical index cytochrome P450 (CYP) 3A substrate, demonstrated that ensitrelvir...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Ryosuke, Sonoyama, Takuhiro, Fukuhara, Takahiro, Kuwata, Aya, Matsuzaki, Takanobu, Matsuo, Yumiko, Kubota, Ryuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177727/
https://www.ncbi.nlm.nih.gov/pubmed/37171749
http://dx.doi.org/10.1007/s40261-023-01265-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177727/
https://www.ncbi.nlm.nih.gov/pubmed/37171749
http://dx.doi.org/10.1007/s40261-023-01265-8

Ejemplares similares